 Robert Neumann
Concepts (94)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Ischemia | 4 | 2025 | 340 | 0.480 |
Why?
| | Daptomycin | 1 | 2012 | 18 | 0.400 |
Why?
| | Oxazolidinones | 1 | 2012 | 15 | 0.400 |
Why?
| | Acetamides | 1 | 2012 | 36 | 0.390 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 2012 | 70 | 0.380 |
Why?
| | Critical Illness | 3 | 2023 | 804 | 0.240 |
Why?
| | Brain Injuries | 2 | 2023 | 494 | 0.240 |
Why?
| | Hyperoxia | 2 | 2023 | 90 | 0.230 |
Why?
| | Interleukin-6 | 2 | 2025 | 778 | 0.210 |
Why?
| | Anti-Bacterial Agents | 2 | 2018 | 1798 | 0.210 |
Why?
| | Ischemic Attack, Transient | 1 | 2023 | 66 | 0.190 |
Why?
| | Spinal Cord Vascular Diseases | 1 | 2018 | 3 | 0.150 |
Why?
| | Stroke | 2 | 2023 | 1133 | 0.150 |
Why?
| | Vasculitis, Central Nervous System | 1 | 2018 | 14 | 0.150 |
Why?
| | Antibodies, Antineutrophil Cytoplasmic | 1 | 2018 | 36 | 0.150 |
Why?
| | Subarachnoid Hemorrhage | 1 | 2018 | 66 | 0.150 |
Why?
| | Intracranial Pressure | 1 | 2018 | 47 | 0.140 |
Why?
| | Vancomycin | 1 | 2018 | 82 | 0.140 |
Why?
| | Brain Injuries, Traumatic | 1 | 2023 | 355 | 0.140 |
Why?
| | Respiration, Artificial | 2 | 2021 | 642 | 0.140 |
Why?
| | Piracetam | 1 | 2017 | 13 | 0.140 |
Why?
| | Hemofiltration | 1 | 2017 | 30 | 0.130 |
Why?
| | Microbial Sensitivity Tests | 1 | 2018 | 357 | 0.130 |
Why?
| | Intracranial Hemorrhages | 1 | 2017 | 85 | 0.130 |
Why?
| | Cerebellar Diseases | 1 | 2016 | 23 | 0.130 |
Why?
| | Aneurysm, Ruptured | 1 | 2016 | 35 | 0.130 |
Why?
| | Oxygen | 1 | 2021 | 930 | 0.130 |
Why?
| | Intracranial Arteriovenous Malformations | 1 | 2016 | 50 | 0.130 |
Why?
| | Intracranial Aneurysm | 1 | 2016 | 97 | 0.120 |
Why?
| | Anticonvulsants | 1 | 2017 | 215 | 0.120 |
Why?
| | Wounds and Injuries | 1 | 2021 | 755 | 0.110 |
Why?
| | Embolization, Therapeutic | 1 | 2016 | 229 | 0.110 |
Why?
| | Cerebral Ventriculitis | 1 | 2012 | 4 | 0.100 |
Why?
| | Injections, Intraventricular | 1 | 2012 | 55 | 0.100 |
Why?
| | Vancomycin Resistance | 1 | 2012 | 16 | 0.100 |
Why?
| | Linezolid | 1 | 2012 | 20 | 0.100 |
Why?
| | Enterococcus faecium | 1 | 2012 | 20 | 0.100 |
Why?
| | Middle Aged | 11 | 2025 | 33239 | 0.100 |
Why?
| | Endovascular Procedures | 1 | 2016 | 315 | 0.100 |
Why?
| | Perfusion Imaging | 1 | 2012 | 58 | 0.100 |
Why?
| | Radiographic Image Enhancement | 1 | 2012 | 58 | 0.100 |
Why?
| | Cerebral Angiography | 1 | 2012 | 109 | 0.090 |
Why?
| | Administration, Intravenous | 1 | 2012 | 155 | 0.090 |
Why?
| | Drainage | 1 | 2012 | 171 | 0.090 |
Why?
| | Hospital Communication Systems | 1 | 2010 | 6 | 0.090 |
Why?
| | Drug Therapy, Combination | 1 | 2012 | 1062 | 0.080 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2012 | 2052 | 0.070 |
Why?
| | Male | 10 | 2025 | 67330 | 0.070 |
Why?
| | Aged, 80 and over | 4 | 2025 | 7593 | 0.070 |
Why?
| | Brain | 1 | 2018 | 2664 | 0.070 |
Why?
| | Inpatients | 1 | 2010 | 496 | 0.060 |
Why?
| | Patient Care Team | 1 | 2010 | 626 | 0.060 |
Why?
| | Aged | 6 | 2025 | 23808 | 0.060 |
Why?
| | Humans | 13 | 2025 | 136803 | 0.050 |
Why?
| | Treatment Outcome | 2 | 2023 | 10748 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 1 | 2012 | 2668 | 0.050 |
Why?
| | Female | 8 | 2025 | 72816 | 0.040 |
Why?
| | Tissue Plasminogen Activator | 1 | 2023 | 225 | 0.040 |
Why?
| | Oximetry | 1 | 2021 | 96 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2025 | 1936 | 0.040 |
Why?
| | Patient Outcome Assessment | 1 | 2021 | 131 | 0.040 |
Why?
| | Adult | 6 | 2023 | 37643 | 0.040 |
Why?
| | Time Factors | 2 | 2025 | 6809 | 0.040 |
Why?
| | Thorax | 1 | 2018 | 49 | 0.040 |
Why?
| | Decision Support Systems, Clinical | 1 | 2021 | 223 | 0.040 |
Why?
| | Pressure | 1 | 2018 | 221 | 0.030 |
Why?
| | Guideline Adherence | 1 | 2021 | 546 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2018 | 785 | 0.030 |
Why?
| | Cerebrovascular Circulation | 1 | 2018 | 241 | 0.030 |
Why?
| | Pilot Projects | 1 | 2021 | 1693 | 0.030 |
Why?
| | Hypoxia | 1 | 2021 | 1112 | 0.030 |
Why?
| | Biomarkers | 1 | 2025 | 4145 | 0.030 |
Why?
| | Seizures | 1 | 2017 | 425 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2016 | 1231 | 0.030 |
Why?
| | Hemodynamics | 1 | 2018 | 1110 | 0.030 |
Why?
| | Quality Improvement | 1 | 2021 | 1163 | 0.020 |
Why?
| | Evidence-Based Medicine | 1 | 2016 | 739 | 0.020 |
Why?
| | False Positive Reactions | 1 | 2012 | 115 | 0.020 |
Why?
| | Prospective Studies | 1 | 2023 | 7573 | 0.020 |
Why?
| | Retrospective Studies | 2 | 2023 | 15510 | 0.020 |
Why?
| | Early Diagnosis | 1 | 2010 | 241 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2012 | 1481 | 0.020 |
Why?
| | Magnetics | 1 | 1987 | 48 | 0.020 |
Why?
| | Auditory Pathways | 1 | 1987 | 52 | 0.020 |
Why?
| | Program Evaluation | 1 | 2010 | 889 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2010 | 2022 | 0.010 |
Why?
| | Brain Mapping | 1 | 1987 | 504 | 0.010 |
Why?
| | Attitude of Health Personnel | 1 | 2010 | 1163 | 0.010 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2010 | 1322 | 0.010 |
Why?
| | Prognosis | 1 | 2010 | 4013 | 0.010 |
Why?
| | Colorado | 1 | 2010 | 4515 | 0.010 |
Why?
| | Evoked Potentials, Auditory | 1 | 1987 | 180 | 0.000 |
Why?
| | Reaction Time | 1 | 1987 | 412 | 0.000 |
Why?
| | Magnetic Resonance Imaging | 1 | 1987 | 3556 | 0.000 |
Why?
|
|
Neumann's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|